Retinal Disease

Pre-cataract surgery OCT means happier patient outcomesBecause a variety of vision-limiting macular pathologies are detectable only with OCT, this imaging should be performed in all patients undergoing cataract surgery.
High-res device gives retinal imaging a faceliftRetinal disease has been given a new face thanks to increased details of the adaptive optics scanning laser ophthalmoscope (AO-SLO), according to Mina Chung, MD.
Aflibercept performance consistent in DME regardless of prior anti-VEGF therapyOutcomes from a study of intravitreal aflibercept were evaluated for patients with and without prior anti-vascular endothelial growth factor therapy for diabetic macular edema.
Editor’s Blog: Forget the future, diabetes is an epidemic nowAs part of Ophthalmology Times’ coverage of the 14th EURETINA Congress in London this week, Group Content Director Mark L. Dlugoss writes this blog.
Navigated laser for DME reduces anti-VEGF re-treatment ratePhotocoagulation with a navigated laser is safe and significantly reduces the need for further anti-vascular endothelial growth factor injections in patients with diabetic macular edema.
Managing oxygen levels in preterm infantsFindings from recent clinical trials are providing some guidance on oxygen management in preterm infants.
Nutritional therapy may fuel outcomes for moderate AMDAn analysis of patient data and DNA from the Age-Related Eye Disease Study (AREDS) indicates that two genetic polymorphisms predict a differential response to antioxidants and zinc, the components of the AREDS formulation.
Melvin Rubin, former AAO president, diesMelvin L. Rubin, MD, a former president of the American Academy of Ophthalmology (AAO), died Sunday, Feb. 23 at his home at the age of 81.
How cost utility justifies retinal detachment repairRepair of retinal detachment is cost effective, especially when compared with injection-based treatments.
Exploring new therapies for neovascular AMDCombination treatment for neovascular age-related macular degeneration is more likely to provide more favorable results by eliminating vascular endothelial growth factor and possibly causing true regression of choroidal neovascularization, reducing the risk of visual loss.